PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

NCT05530200 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Solid Tumor

Interventions

RADIATION: Hypofractionated radiotherapy
DRUG: PD-L1 inhibitor
DRUG: GM-CSF
DRUG: IL-2

Sponsor

Second Affiliated Hospital of Soochow University